Peelife Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 03-07-2024
- Paid Up Capital ₹ 0.50 M
as on 03-07-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.50 Cr
as on 03-07-2024
- Revenue -74.37%
(FY 2022)
- Profit -62.26%
(FY 2022)
- Ebitda -87.89%
(FY 2022)
- Net Worth -17.25%
(FY 2022)
- Total Assets -18.80%
(FY 2022)
About Peelife Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹1.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ujjawal Garg, Mohit Saini, and Beenu Jain serve as directors at the Company.
- CIN/LLPIN
U74120UP2012PTC049730
- Company No.
049730
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Apr 2012
- Date of AGM
22 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Rampur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Peelife Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ujjawal Garg  | Director | 11-Apr-2023 | Current |
| Mohit Saini | Director | 05-May-2023 | Current |
| Beenu Jain | Director | 05-May-2023 | Current |
Financial Performance of Peelife Pharmaceuticals.
Peelife Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 74.37% decrease. The company also saw a substantial fall in profitability, with a 62.26% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Peelife Pharmaceuticals?
In 2020, Peelife Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lifeway Pharmaceuticals Private LimitedActive 11 years 6 monthsUjjawal Garg and Mohit Saini are mutual person
- Glenford Pharmaceuticals Private LimitedActive 5 years 1 month
Mohit Saini and Beenu Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 12 Mar 2013 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Peelife Pharmaceuticals?
Unlock and access historical data on people associated with Peelife Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Peelife Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Peelife Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
